Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Octreotide sustained release - Biodexa Pharmaceuticals

Next Previous
X
Search
Drug Profile

Octreotide sustained release - Biodexa Pharmaceuticals

Alternative Names: MTD-201; Q-Octreotide

Latest Information Update: 16 May 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Midatech
  • Developer Biodexa Pharmaceuticals
  • Class Antidiarrhoeals; Antineoplastics; Antisecretories; Cyclic peptides; Eye disorder therapies; Indoles; Somatostatins
  • Mechanism of Action Growth hormone-releasing hormone inhibitors; Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Acromegaly; Neuroendocrine tumours

Highest Development Phases

  • Discontinued Acromegaly; Malignant carcinoid syndrome; Neuroendocrine tumours

Most Recent Events

  • 07 Apr 2020 Octreotide sustained release is available for licensing as of 07 Apr 2020
  • 07 Apr 2020 Discontinued - Phase-I for Acromegaly (Combination therapy, In volunteers) in United Kingdom (IM)
  • 07 Apr 2020 Discontinued - Phase-I for Acromegaly (Combination therapy, In volunteers) in United Kingdom (SC)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top